Navigation Links
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Date:3/26/2009

eight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control and low incidence of hypoglycemia when used with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include n
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... SHANGHAI, Aug. 10 /PRNewswire-Asia-FirstCall/ ... ("China-Biotics," "the Company"), a leading Chinese firm,specializing ... of probiotics products, today announced that the ... has been,awarded the High-Technology Enterprise Certificate (the ...
... /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... Patent and Trademark Office (PTO) has issued United ... Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method ... to treat certain cancers. The patent, licensed from ...
... ... launched its revolutionary Trusted LASIK Surgeons directory service and website at ... improve their vision and find a highly qualified eye surgeon who can ... directory apart is a unique screening process ensuring that only those who ...
Cached Biology Technology:China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 2Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 3Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 4Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 5Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 6Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 7Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 8
(Date:8/29/2014)... Texas Medical Branch at Galveston has gone on record stating ... monkeys against a lethal dose of Ebola virus up to ... is severe. , Thomas Geisbert, professor of microbiology and immunology, ... in Ebola treatment research. The filoviruses known as Ebola virus ... with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... To understand how the repeated climatic shifts over ... patterns of genetic diversity, a team of researchers ... Dr. Ana Carnaval developed a new biodiversity metric ... to which the genetic variation within species is ... assistant professor of biology, and 14 other researchers ...
(Date:8/29/2014)... Dartmouth researchers explored the type and number of connections ... assortativity plays on robustness in a study published in ... study found that the assortativity signature contributes to a ... seems that varying the out-out assortativity of TFN models ... of the other three types of assortativity," said Dov ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2Assortativity signatures of transcription factor networks contribute to robustness 2
... superstars of urban landscapes. In addition to their intrinsic ... pollution, provide habitat for wildlife, increase property values, and ... trees decrease energy usage in urban buildings, absorb carbon ... that researchers around the world are working to find ...
... STATION, TXLandscape trees are increasingly being produced using ... practices. In contrast to field production techniques, successful ... in which trees are sequentially transferred to larger ... Problems can arise when trees are ...
... Behaviour Using Accelerometry in Cane Toads Bufo marinus ... were introduced to Australia as a control agent but now ... they enter. Predictive models that can give expansion rates as ... to maximise control efficiency but to date no study has ...
Cached Biology News:Low-tech cool: Shade trees for subtropical streets 2Planting depth affects popular landscape tree 2Cane toad accelerometry and more 2Cane toad accelerometry and more 3Cane toad accelerometry and more 4Cane toad accelerometry and more 5Cane toad accelerometry and more 6
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: